Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ViroPharma gets FDA nod for Cinryze plant expansion at last

This article was originally published in Scrip

Executive Summary

ViroPharma has secured US FDA approval for expanded manufacturing of Cinryze (human C1 esterase inhibitor), under a supplement to its BLA for industrial scale manufacturing changes. The firm had previously had two knockbacks from the agency in the form of complete response letters in 2010 and earlier this year (, 8 February 2012). The manufacturing expansion at a site in the Netherlands is needed to meet rising US demand for the product, and will enable it to "to ensure the market is fully served and build adequate safety stock levels", said COO Dan Soland. The added industrial scale process will also give it the flexibility to increase production further still through additional shifts if necessary, he noted. Cinryze has been available in the US for the prevention of angioedema attacks in patients with hereditary angioedema since 2008. In Europe it was approved last year for a broader treatment and prevention indication. Production for the European market is located at a separate site.

You may also be interested in...

Gaming Whiz Brings AI Smarts To Drug Discovery

GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.

The Top 10 Best-Selling Drugs of 2019

INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market. 

Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus

Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts